HELP Stock Analysis: Cybin Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 893m USD | 12M Return: 112.8% | CA23256X4075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.7M
Warnings
Tailwinds
Seasonality 6.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cybin Inc. (HELP) is a Canadian clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for neuropsychiatric conditions. Its core pipeline utilizes deuterated molecules, which are chemically modified to potentially improve the metabolic profile and duration of action compared to traditional psychedelic compounds.
The company’s lead candidate, CYB003, is a deuterated psilocybin analog currently entering Phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). Additionally, Cybin is advancing CYB004, a deuterated DMT molecule in Phase 2 trials for Generalized Anxiety Disorder, alongside several preclinical programs targeting central nervous system disorders.
The psychedelic medicine sector operates under a high-risk, high-reward model characterized by long regulatory approval timelines and significant capital requirements for late-stage clinical trials. For a deeper look at the underlying fundamentals, you may find ValueRay to be a useful resource for further research. To support its pivotal Phase 3 program, Cybin maintains a strategic partnership with Segal Trials to facilitate multinational clinical data collection.
- CYB003 Phase 3 clinical trial results for Major Depressive Disorder
- FDA Breakthrough Therapy Designation accelerates regulatory approval timeline
- Cash runway and future equity raises impact capital structure
- Competitive landscape for psychedelic-based therapeutics and deuterated psilocybin analogs
| Net Income: -183.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.60 > 0.02 and ΔFCF/TA 3.33 > 1.0 |
| NWC/Revenue: 13.5k% < 20% (prev 20.1k%; Δ -6.60k% < -1%) |
| CFO/TA -0.59 > 3% & CFO -153.0m > Net Income -183.3m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 10.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.3m) vs 12m ago 133.6% < -2% |
| Gross Margin: 89.88% > 18% (prev 0.0%; Δ 89.88% > 0.5%) |
| Asset Turnover: 0.63% > 50% (prev 0.31%; Δ 0.32% > 0%) |
| Interest Coverage Ratio: -43.83 > 6 (EBIT TTM -177.2m / Interest Expense TTM 4.04m) |
| A: 0.67 (Total Current Assets 192.5m - Total Current Liabilities 17.5m) / Total Assets 259.3m |
| B: -1.68 (Retained Earnings -436.8m / Total Assets 259.3m) |
| C: -0.86 (EBIT TTM -177.2m / Avg Total Assets 207.0m) |
| D: 13.78 (Book Value of Equity 241.8m / Total Liabilities 17.5m) |
| Altman-Z'' = 7.65 = AAA |
| DSRI: 0.61 (Receivables 5.03m/3.01m, Revenue 1.30m/472k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.81 (AQ_t 0.26 / AQ_t-1 0.32) |
| SGI: 2.75 (Revenue 1.30m / 472k) |
| TATA: -0.12 (NI -183.3m - CFO -153.0m) / TA 259.3m) |
| Beneish M = -2.22 (Cap -4..+1) = BBB |
As of September 10, 2026, the stock is trading at USD 13.68 with a total of 1,717,425 shares traded. Over the past week, the price has changed by +17.93%, over one month by +36.66%, over three months by +248.98% and over the past year by +112.75%.
Current recommended Stop Loss: 12.70 (which is 7.2% or 1.2 ATR below the current price).
Cybin Common Stock has no consensus analysts rating.
Market Cap CAD = 1.23b (892.8m USD * 1.3806 USD.CAD)
P/S = 16436.3617
P/B = 3.5616
Revenue TTM = 1.30m CAD
EBIT TTM = -177.2m CAD
EBITDA TTM = -177.0m CAD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.07b CAD (1.23b + (null Debt) - CCE 166.2m)
Interest Coverage Ratio = -43.83 (Ebit TTM -177.2m / Interest Expense TTM 4.04m)
EV/FCF = -6.90x (Enterprise Value 1.07b / FCF TTM -154.6m)
FCF Yield = -14.50% (FCF TTM -154.6m / Enterprise Value 1.07b)
FCF Margin = -11.9k% (FCF TTM -154.6m / Revenue TTM 1.30m)
Net Margin = -14.1k% (Net Income TTM -183.3m / Revenue TTM 1.30m)
Gross Margin = 89.88% ((Revenue TTM 1.30m - Cost of Revenue TTM 131k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.11 (Enterprise Value 1.07b / Total Assets 259.3m)
Interest Expense / Debt = unknown (Interest Expense 4.04m / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -140.0m (EBIT -177.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.97 (Total Current Assets 192.5m / Total Current Liabilities 17.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -177.0m)
Debt / FCF = unknown (Net Debt none / FCF TTM -154.6m)
Total Stockholder Equity = 258.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -88.52% (Net Income -183.3m / Total Assets 259.3m)
RoE = -70.99% (Net Income TTM -183.3m / Total Stockholder Equity 258.2m)
RoCE = -73.27% (EBIT -177.2m / Capital Employed (Total Assets 259.3m - Current Liab 17.5m))
RoIC = -57.90% (negative operating profit) (NOPAT -140.0m / Invested Capital 241.7m)
WACC = 13.22% (E(1.23b)/V(1.23b) * Re(13.22%) + (debt-free company))
Discount Rate = 13.22% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 78.12 | Cagr: 53.32%
[DCF] Fair Price = unknown (Cash Flow -154.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.94 | Chg30d=+5.59% | Revisions=-17% | Analysts=5
EPS next Quarter (2026-12-31): EPS=-0.88 | Chg30d=+3.10% | Revisions=+17% | Analysts=5
EPS current Year (2027-03-31): EPS=-3.71 | Chg30d=+6.66% | Revisions=-17% | GrowthEPS=+37.4% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.54 | Chg30d=+23.08% | Revisions=+0% | GrowthEPS=+31.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -7% (up=5, down=6)